IBIO-600 — Safety, Research, Risks & Legal Status

Not medical advice. IBIO-600 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	IBIO-600; anti-myostatin/GDF-11 monoclonal antibody (AstralBio/iBio)
Category	Peptide (research chemical)
Drug class	Ultra-long-acting recombinant anti-myostatin/GDF-11 monoclonal antibody
Developer	Discovered by AstralBio, Inc.; licensed to and in development by iBio, Inc. (NASDAQ: IBIO)
Development stage	Phase 1 clinical trial (first-in-human, single ascending dose; Australia, initiated Q2 2026)
Preclinical half-life (NHP)	~40-52 days following single subcutaneous dose
Preclinical lean mass effect (NHP)	Up to 5.1% increase (company-disclosed; not peer-reviewed)
Route of administration	Subcutaneous injection; engineered for potential 2-4 doses per year
US legal status	Unapproved investigational drug. Not approved in the United States or any jurisdiction. Currently in Phase 1 clinical trials in Australia (2026). No FDA IND or NDA has been publicly disclosed. Not available for human use outside of authorized clinical trials. Not a dietary supplement or over-the-counter product.

What is IBIO-600?

IBIO-600 is an ultra-long-acting recombinant monoclonal antibody (mAb) that targets both myostatin and GDF-11 (growth differentiation factor 11), two closely related members of the TGF-beta superfamily that function as negative regulators of skeletal muscle mass. It was discovered by AstralBio, Inc. using a proprietary antibody discovery platform and is being developed under an exclusive license by iBio, Inc. (NASDAQ: IBIO). The compound is designed for subcutaneous injection with an engineered extended half-life intended to allow very infrequent dosing - potentially two to four administrations per year. Its primary proposed indication is preservation or augmentation of lean body mass in the context of obesity and cardiometabolic disease, particularly in settings where GLP-1 receptor agonists or other interventions may cause muscle loss alongside fat loss.

How it works

IBIO-600 is a dual-targeting monoclonal antibody that binds and neutralizes both myostatin (GDF-8) and GDF-11, preventing these ligands from activating their downstream signaling pathway through activin type II receptors (ActRII) and the SMAD2/3 transcriptional cascade. By blocking this pathway, the antibody is intended to relieve inhibitory tone on satellite cell activation, muscle fiber hypertrophy, and muscle protein synthesis. The dual-target design is notable because GDF-11 shares substantial structural homology with myostatin and may exert overlapping inhibitory effects on muscle; blocking only myostatin could allow compensatory GDF-11 activity to partially offset gains. The ultra-long-acting pharmacokinetic profile is the result of antibody engineering, with preclinical data in non-human primates showing a terminal half-life of approximately 40 to 52 days following a single subcutaneous dose.

Background & history

Myostatin was identified as a negative regulator of muscle mass in the late 1990s following knockout mouse studies (McPherron et al., 1997). The field attracted intense pharmaceutical interest, with multiple companies attempting to develop myostatin inhibitors for muscular dystrophy, cachexia, sarcopenia, and later obesity-associated muscle loss. Several earlier programs (stamulumab, bimagrumab, landogrozumab) reached clinical stages with mixed results, and no myostatin inhibitor has achieved regulatory approval as of 2026. AstralBio developed IBIO-600 using a proprietary discovery platform and entered an exclusive license agreement with iBio, Inc. in January 2025 for an upfront payment of $750,000 (paid in iBio stock) plus potential development and commercialization milestones of up to $28 million. iBio received Clinical Trial Notification acknowledgement from Australia's Therapeutic Goods Administration (TGA) and ethics approval in April 2026, and first human participants were dosed in Q2 2026, making iBio a clinical-stage company for the first time.

What the research says

IBIO-600 is in very early clinical development. As of mid-2026, the only human data comes from a Phase 1 single ascending dose (SAD) trial in Australia, which is ongoing and has not reported results. No peer-reviewed publications on IBIO-600 have been identified, which is stage-appropriate for a compound entering first-in-human studies. Preclinical data disclosed by iBio in investor and press materials includes: non-human primate studies showing a half-life of 40-52 days following single subcutaneous administration; dose-dependent lean mass increases of up to 5.1% in NHP; associated reductions in fat mass; and in vitro demonstration of potent myostatin inhibition in human muscle cell precursors. These are company-disclosed preclinical findings and have not been independently peer-reviewed. The broader myostatin inhibitor class has a mixed clinical track record - bimagrumab (anti-ActRII) showed meaningful lean mass gains but the clinical program has been complex, and no drug in the class has reached approval. IBIO-600's dual myostatin/GDF-11 targeting strategy is a mechanistic differentiation from some earlier agents, but whether this translates to superior clinical outcomes is entirely unknown at this stage.

Reported effects

Increased lean body mass (up to 5.1% in NHP preclinical studies; no human efficacy data yet)
Reduction in fat mass (observed in NHP preclinical studies; no human data)
Ultra-long pharmacokinetic profile: half-life ~40-52 days in non-human primates, enabling infrequent dosing
Sustained pharmacodynamic activity over time in preclinical models
In vitro inhibition of myostatin signaling in human muscle cell precursors
All efficacy observations are preclinical or mechanistic only; no human efficacy data available as of mid-2026

Dosing & administration (informational)

The Phase 1 trial is evaluating single ascending doses in a controlled clinical setting. Preclinical data suggests the compound may be dosed as infrequently as 2-4 times per year based on its engineered half-life. No human dosing regimen has been established, and no dose has been identified as safe or effective in humans. This information is provided for reference only. Consult a licensed clinician for any therapeutic decisions - no self-administration protocol exists or should be attempted for an investigational mAb at this stage of development.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No clinical safety data available; Phase 1 trial is the first formal human safety assessment
Preclinical safety profile has not been publicly disclosed in detail by iBio or AstralBio
Myostatin inhibitors as a drug class have generally shown tolerability in trials, but class effects do not necessarily predict IBIO-600-specific outcomes
Potential theoretical risks of myostatin/GDF-11 inhibition include effects on cardiac muscle (GDF-11 has roles beyond skeletal muscle), reproductive biology, and tissue homeostasis - these have not been characterized for IBIO-600 specifically
Monoclonal antibodies as a class carry risks including immunogenicity and injection-site reactions; these have not been assessed for IBIO-600 in humans
The Phase 1 trial in overweight/obese adults is a randomized, double-blind, placebo-controlled single ascending dose design - primary endpoints are safety and tolerability
No consumer or self-administration use is appropriate at this investigational stage

Drug & supplement interactions

N
o
h
u
m
a
n
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
e
x
i
s
t
s
.
T
h
e
o
r
e
t
i
c
a
l
c
o
n
s
i
d
e
r
a
t
i
o
n
s
i
n
c
l
u
d
e
a
d
d
i
t
i
v
e
o
r
s
y
n
e
r
g
i
s
t
i
c
e
f
f
e
c
t
s
i
f
c
o
m
b
i
n
e
d
w
i
t
h
o
t
h
e
r
a
n
a
b
o
l
i
c
o
r
a
n
t
i
-
c
a
t
a
b
o
l
i
c
a
g
e
n
t
s
,
a
n
d
p
o
t
e
n
t
i
a
l
i
n
t
e
r
a
c
t
i
o
n
w
i
t
h
b
i
o
l
o
g
i
c
s
t
h
a
t
s
h
a
r
e
d
o
w
n
s
t
r
e
a
m
s
i
g
n
a
l
i
n
g
p
a
t
h
w
a
y
s
(
e
.
g
.
,
a
c
t
i
v
i
n
p
a
t
h
w
a
y
m
o
d
u
l
a
t
o
r
s
)
.
A
s
a
m
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
y
,
c
y
t
o
c
h
r
o
m
e
P
4
5
0
-
m
e
d
i
a
t
e
d
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
a
r
e
n
o
t
e
x
p
e
c
t
e
d
,
b
u
t
t
h
i
s
h
a
s
n
o
t
b
e
e
n
s
t
u
d
i
e
d
i
n
h
u
m
a
n
s
f
o
r
I
B
I
O
-
6
0
0
.

Who should avoid it

Self-administration outside a clinical trial - no established human safety profile
Use in individuals with known hypersensitivity to monoclonal antibodies
Pregnancy and lactation - GDF-11 has developmental biology roles; effects are uncharacterized
Concurrent use with other myostatin/activin pathway modulators without clinical oversight
Sourcing from non-clinical-trial channels - no legitimate supply exists outside the trial

How it is commonly combined

No stacking data exists for IBIO-600 in humans. The compound is in Phase 1 safety evaluation only. The commercial rationale often discussed in the context of myostatin inhibitors is use alongside GLP-1 receptor agonists to preserve lean mass during weight loss, but this combination has not been studied for IBIO-600 and should not be attempted outside a clinical trial.

Legal & regulatory. Unapproved investigational drug. Not approved in the United States or any jurisdiction. Currently in Phase 1 clinical trials in Australia (2026). No FDA IND or NDA has been publicly disclosed. Not available for human use outside of authorized clinical trials. Not a dietary supplement or over-the-counter product.

Quality & harm reduction

Safer, legal alternative we recommend

Creatine Supreme. For supporting muscle mass and strength, creatine monohydrate is the most evidence-backed legal option, with decades of safety data - ours ships from the Peptropix line.

See our recommended pick

Find IBIO-600 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What makes IBIO-600 different from earlier myostatin inhibitors like stamulumab or bimagrumab?

IBIO-600 targets both myostatin (GDF-8) and GDF-11 simultaneously, whereas several earlier agents targeted myostatin alone or the ActRII receptor more broadly. The rationale is that GDF-11 shares structural homology with myostatin and could theoretically compensate if only myostatin is blocked. Additionally, IBIO-600 is engineered for an ultra-long half-life (~40-52 days in NHP), enabling very infrequent dosing. Whether these design choices translate to superior clinical outcomes is unknown - no human efficacy data exists yet.

Is IBIO-600 approved or available for purchase?

No. IBIO-600 is an unapproved investigational drug currently in Phase 1 trials in Australia. It is not available for human use outside of authorized clinical trials, and no legitimate commercial supply exists. Any product marketed under this name outside a clinical setting should be regarded with extreme skepticism.

What dose should I take?

No safe or effective dose has been established in humans. IBIO-600 is in Phase 1 dose-escalation trials precisely to determine these parameters. Consult a licensed clinician for any therapeutic decision involving body composition or muscle mass. Self-administration of an investigational monoclonal antibody is not appropriate.

What does the Phase 1 trial actually measure?

The trial is a randomized, double-blind, placebo-controlled single ascending dose study in overweight and obese adults. Primary endpoints are safety and tolerability. Secondary endpoints include pharmacokinetics (how the drug moves through the body) and pharmacodynamics (whether it produces measurable biological effects on myostatin/GDF-11 pathway activity and body composition markers). Efficacy is not a primary endpoint at this stage.

What is the evidence base for the myostatin inhibitor class more broadly?

The class has a substantial preclinical foundation and a mixed clinical track record. Bimagrumab, which blocks the ActRII receptor rather than myostatin directly, has shown meaningful lean mass preservation and fat loss in Phase 2 trials in obesity, but no drug in the class has received regulatory approval. Stamulumab (Wyeth) failed to meet primary endpoints in Becker muscular dystrophy. The class's complexity arises partly from the pleiotropic roles of TGF-beta family signaling beyond muscle. IBIO-600 enters this context as a differentiated candidate, but its clinical outcome is entirely uncertain.

Why are iBio running the trial in Australia rather than the US?

Australia's Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) scheme allows Phase 1 trials to initiate relatively quickly after ethics committee approval, without requiring pre-trial TGA review of the clinical trial application. This pathway is widely used by early-stage biopharmaceutical companies globally to accelerate first-in-human timelines. US development and IND filing timelines for IBIO-600 have not been publicly disclosed as of mid-2026.

References & further reading

ClinicalTrials.gov: search terms 'IBIO-600' or 'iBio myostatin Phase 1 Australia 2026'
PubMed: search terms 'myostatin GDF-11 dual inhibition monoclonal antibody' and 'bimagrumab clinical trial lean mass obesity' for class context
PubMed: McPherron AC et al. myostatin muscle mass regulation (foundational class literature)
ClinicalTrials.gov: search terms 'bimagrumab obesity lean mass' for related class clinical precedent
PubMed: search terms 'anti-myostatin antibody sarcopenia cachexia clinical trial' for class-level evidence base